$242 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 72 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MSACW | Exit | Medicus Sciences Acquisition Corpwarrants | $0 | – | -49,990 | -100.0% | -0.00% | – |
| EVGN | Exit | Evogene Ltdequities | $0 | – | -150,361 | -100.0% | -0.03% | – |
| GOSS | Exit | Gossamer Bio Incequities | $0 | – | -100,000 | -100.0% | -0.06% | – |
| QURE | Exit | Uniqure NVequities | $0 | – | -10,000 | -100.0% | -0.06% | – |
| PRAX | Exit | Praxis Precision Medicines Incequities | $0 | – | -98,409 | -100.0% | -0.07% | – |
| Exit | Braze Incequities | $0 | – | -10,000 | -100.0% | -0.08% | – | |
| WVE | Exit | WAVE Life Sciences Ltdequities | $0 | – | -50,000 | -100.0% | -0.10% | – |
| MGTX | Exit | Meiragtx Holdings Plcequities | $0 | – | -56,672 | -100.0% | -0.11% | – |
| IMUX | Exit | Immunic Incequities | $0 | – | -350,656 | -100.0% | -0.14% | – |
| DSGN | Exit | Design Therapeutics Incequities | $0 | – | -57,025 | -100.0% | -0.17% | – |
| CDXS | Exit | Codexis Incequities | $0 | – | -144,737 | -100.0% | -0.19% | – |
| STXS | Exit | Stereotaxis Incequities | $0 | – | -354,925 | -100.0% | -0.21% | – |
| AXSM | Exit | Axsome Therapeutics Incequities | $0 | – | -10,000 | -100.0% | -0.22% | – |
| CYTK | Exit | Cytokinetics Incequities | $0 | – | -17,500 | -100.0% | -0.23% | – |
| ALT | Exit | Altimmune Incequities | $0 | – | -50,546 | -100.0% | -0.24% | – |
| VERU | Exit | Veru Inc.put | $0 | – | -175,000 | -100.0% | -0.26% | – |
| AVXL | Exit | Anavex Life Science Corpcall | $0 | – | -102,600 | -100.0% | -0.27% | – |
| AVTE | Exit | Aerovate Therapeutics Incequities | $0 | – | -36,906 | -100.0% | -0.31% | – |
| CMPX | Exit | Compass Therapeutics Inc.equities | $0 | – | -268,307 | -100.0% | -0.39% | – |
| AMYT | Exit | Amryt Pharma PLCequities | $0 | – | -192,995 | -100.0% | -0.40% | – |
| SGEN | Exit | Seagen Incequities | $0 | – | -11,016 | -100.0% | -0.40% | – |
| CTIC | Exit | CTI BioPharma Corpequities | $0 | – | -254,361 | -100.0% | -0.44% | – |
| ISEE | Exit | IVERIC bio Incequities | $0 | – | -88,243 | -100.0% | -0.54% | – |
| HZNP | Exit | Horizon Therapeutics Plcequities | $0 | – | -23,054 | -100.0% | -0.75% | – |
| PHR | Exit | Phreesia Incequities | $0 | – | -85,390 | -100.0% | -0.79% | – |
| CRNX | Exit | Crinetics Pharmaceuticals Incequities | $0 | – | -152,747 | -100.0% | -0.80% | – |
| ASND | Exit | Ascendis Pharma A/Sequities | $0 | – | -23,151 | -100.0% | -0.81% | – |
| RNA | Exit | Avidity Biosciences Incequities | $0 | – | -128,000 | -100.0% | -0.81% | – |
| PCVX | Exit | Vaxcyte Incequities | $0 | – | -83,135 | -100.0% | -1.14% | – |
| PRTA | Exit | Prothena Corporation PLCequities | $0 | – | -71,706 | -100.0% | -1.24% | – |
| BCAB | Exit | Bioatla Incequities | $0 | – | -546,875 | -100.0% | -1.29% | – |
| Exit | GlaxoSmithKline PLCequities | $0 | – | -136,178 | -100.0% | -1.37% | – | |
| Exit | Cincor Pharma Incequities | $0 | – | -395,382 | -100.0% | -1.39% | – | |
| AKRO | Exit | Akero Therapeutics Inccall | $0 | – | -150,000 | -100.0% | -2.35% | – |
| AKRO | Exit | Akero Therapeutics Incput | $0 | – | -150,000 | -100.0% | -2.35% | – |
| MDGL | Exit | Madrigal Parmaceuticals, Inc.put | $0 | – | -30,000 | -100.0% | -2.49% | – |
| IMVT | Exit | Immunovant Incequities | $0 | – | -519,614 | -100.0% | -2.64% | – |
| AVXL | Exit | Anavex Life Science Corpput | $0 | – | -1,007,700 | -100.0% | -2.67% | – |
| RXDX | Exit | Prometheus Bioscience, Inc.put | $0 | – | -172,400 | -100.0% | -5.42% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- SilverArc Capital, LLC #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.